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Compulsive gamblingCompulsive gambling is recognizedwith Parkinson's disease treatmentwith dopamine agonists but has not been
reportedwith antiepilepticmedications (AEMs) in epilepsy. This is the ﬁrst report regarding possible compulsive
gambling, provoked by AEMs in a patient with idiopathic generalized epilepsy, who presented with
nonconvulsive status epilepticus, having previously not achieved seizure control with carbamazepine, valproate,
(VPA), topiramate, gabapentin (GPT), lamotrigine (LTG), and clobazam. Levetiracetam (LEV) was added to VPA
and GPT, which the patient was already taking and LTG subsequently retrialed. Following the reintroduction of
LTG, she lost $4000–5000, which she concealed. With better seizure control, VPA and GPT were withdrawn,
leaving her on LEV and LTG. With increased LTG dosage, she lost $50,000, prompting discovery of her gambling.
© 2013 . Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Compulsive gambling has been reported with treatment of
Parkinson's disease but not with epilepsy. This report provides the
ﬁrst possible connection between gambling and treatment of epilepsy.2. Case
A46-year-old female, diagnosedwith idiopathic generalized epilepsy
at the age of 18, was ﬁrst seen in the clinic in 2000, when she had
nonconvulsive status epilepticus. She had trialed carbamazepine,
valproate (VPA), topiramate, gabapentin (GPT), and lamotrigine (LTG),
prior to attending the clinic, to which had been added clobazamwithout
seizure control. Levetiracetam (LEV) was introduced in 2001, at which
time she was on VPA and GPT. Lamotrigine was reintroduced in 2006,
and both GPT and VPA were stopped in 2009 when her seizure activity
was better controlled.
She was known to have a tendency toward excessive behavior
(shopping, drinking, and exercising) but this predated her epilepsy.
Her father drank alcohol to excess and was largely absent during her
childhood. He attempted suicide and was hospitalized, but there waserms of the Creative Commons
permits non-commercial use,
the original author and source
as St, Chatswood, NSW 2067,
evier B.V. This is an open access articno other premorbid psychiatric history within the family, and the
patient was never diagnosed with a mental illness. She did have an
eating problem, being overweight with difﬁculty dieting.
Following the reintroduction of LTG, she initially lost $4000–$5000 in
gambling, which she could repay. She had, up to this time, successfully
concealed her gambling, but with increased dosage of LTG she lost
$50,000 of her family's assets, thereby provoking serious consequences.
At the time of discovery, she was on LEV 500 mg II B.I.D. (blood level:
31 mg/L, therapeutic) and LTG 200 mg I mane and II nocte (blood
level: 53.6 μmol/L, therapeutic). She was not on dopamine agonists.3. Discussion
GSK (Glaxo Smith Kline) and UCB (United Chemical Belgium) were
contacted, and GSK reported intrusive repetitive behavior (similar to
punding) associated with LTG but that there had been no reports of
excessive gambling. UCB reported that LEV is associated with depres-
sion and other emotional issues, but there are no known cases of gam-
bling with LEV. Evidence of an association between LEV and a genetic
variation in dopaminergic activity and hence the risk for psychiatric
complications has been previously reported [1]. As it is presumed to
be the dopaminergic effect of dopamine agonists that provoke the com-
pulsive gambling in Parkinson's disease, thismay offer a plausible expla-
nation in this case.
Dopaminergic medications, in the form of Madopar (L-dopa com-
binedwith benserazide), have been trialed in 3 patientswith intractable
epilepsy, resulting in seizure reduction in 2 patients, thereby suggesting
possible reinforcement of the hypothesis of a dopaminergicmechanism
of seizure control in idiopathic generalized epilepsy [2,3].le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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dissipated upon stopping LEV [4], which also indicates it to be a poten-
tial provocateur in this case. Lamotrigine has also been associated with
obsessive symptoms, which appeared dose-dependent in one case [5].
In that case, it was hypothesized that LTG inhibited the presynaptic
release of glutamate with altered striatal dopamine uptake, which
again is relevant to the reputed cause of gambling associated with
Parkinson's disease and dopaminergic therapy. Others [6] have also
noted the emergence of obsessional behavior in association with LTG
and questioned glutamatergic regulation. Animal studies have demon-
strated stereotyped behavior provoked by dopaminergic mechanisms
induced by LTG. The hypothesis is that LTG may directly stimulate the
postsynaptic striatal D2 andD1 dopamine receptors or indirectly release
dopamine from the nigostriatal dopamine neurons [7].
These reports, when seen in the context of this patient, raise serious
concerns that this patient's gambling behavior may well be AEM-
provoked and could be due to either the LTG or the LEV or the combina-
tion of both. The emergence of compulsive gambling in Parkinson's
disease is a relatively newly recognized phenomenon and has become
a major focus of patient monitoring. This patient initially concealed
her gambling, andwithout such behavior being recognized as a possible
adverse event of AEMs, it might have remained (and may remain)
unexplained.
4. Conclusion
To our knowledge, this case represents the ﬁrst report of possible
compulsive gambling associated with the use of AEMs, either LTG or
LEV or their combination. It highlights a potential adverse effect of
AEMs that may be more widespread if actively sought as this patient
was able to initially conceal it until the problem became unmanageable.
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